Aldeyra The Market Cap ($37.44 Million)
Market Cap & Net Worth: Aldeyra The (ALDX)
Aldeyra The market cap. Aldeyra The (NASDAQ:ALDX) has a market capitalization of $37.44 Million ($37.44 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22762 globally and #5011 in its home market, demonstrating a -3.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aldeyra The's stock price $0.62 by its total outstanding shares 60326421 (60.33 Million). Also see cash flow conversion of Aldeyra The for how efficiently the company converts equity into cash flow.
Aldeyra The Market Cap History (2015–2026)
Aldeyra The market cap history from 2015 to 2026. Data shows change from $409.01 Million to $37.44 Million (-18.96% CAGR). Check ALDX stock price for real-time trading data and today's change.
Index Memberships
Aldeyra The is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #640 of 976 |
Weight: Aldeyra The's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aldeyra The Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aldeyra The's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ALDX net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ALDX by Market Capitalization
Companies near Aldeyra The in the global market cap rankings as of November 5, 2026. Also see Aldeyra The asset portfolio for a full breakdown of the balance sheet.
Key companies related to Aldeyra The by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Aldeyra The (2015–2026)
Market capitalization of Aldeyra The from 2015 to today. Between 2015 and today, Aldeyra The's market cap moved from $409.01 Million to $ 37.44 Million, with a yearly change of -18.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $37.44 Million | -88.02% |
| 2025 | $312.49 Million | +3.81% |
| 2024 | $301.03 Million | +42.17% |
| 2023 | $211.75 Million | -49.57% |
| 2022 | $419.87 Million | +74.00% |
| 2021 | $241.31 Million | -41.69% |
| 2020 | $413.84 Million | +18.07% |
| 2019 | $350.50 Million | -30.00% |
| 2018 | $500.71 Million | +22.06% |
| 2017 | $410.22 Million | +27.10% |
| 2016 | $322.75 Million | -21.09% |
| 2015 | $409.01 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Aldeyra The was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.44 Million USD |
| MoneyControl | $37.44 Million USD |
| MarketWatch | $37.44 Million USD |
| marketcap.company | $37.44 Million USD |
| Reuters | $37.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary… Read more